The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 19, 2024. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2025.
10-Q for Q3 FY2024, filed Nov 19, 2024
The sections below describe the company as of the FY2023 annual report.
Sells biodegradable bioplastic resins and develops custom polymer formulations for consumer packaging brands, plastics converters and manufacturers.
10-K for FY2023, filed Mar 29, 2024We are a performance polymer company specializing in bioplastic replacements for traditional petroleum-based plastics. Applications for…View ↗
We have core competencies in polymer formulation and application development, fermentation process engineering, thermocatalysis, chemical…View ↗
We currently produce PHA in a fermentation process in which bacteria consume vegetable oil and produce PHA within their cell membranes as…View ↗
Since 2004, we have been producing proprietary plastics using PLA as a base resin. We purchase neat PLA and formulate it into bioplastic…View ↗
Customers buy finished compostable resins, with the sale completed at shipment. For custom research and development, customers generally pay at project start and as milestones are reached.
10-K for FY2023, filed Mar 29, 2024We derive our revenues primarily from: 1) product sales of developed compostable resins based on polyhydroxyalkanoates (“PHA”), polylactic…View ↗
We generally produce and sell finished products, for which we recognize revenue upon shipment, which is typically when control of the…View ↗
R&D service revenues generally involve milestone-based contracts under which we work with a customer to develop a PHA-based solution…View ↗
We recognize a contract liability if we receive consideration (or have the conditional right to receive consideration) in advance of…View ↗
$46.7M
10-K for FY2023, filed Mar 29, 2024
$46.7M ↗
Sells resins to consumer packaging brand owners, plastics converters and manufacturers; it also works directly with consumer-product companies on custom research and development.
10-K for FY2023, filed Mar 29, 2024We have core competencies in polymer formulation and application development, fermentation process engineering, thermocatalysis, chemical…View ↗
Research and Development: We have a number of PHA R&D contracts with global consumer products companies, including Bacardi and Mars…View ↗
Research and Development (“R&D”) and Tolling Services: Our technology team partners with global consumer product companies to develop…View ↗
No. It lost $155.5M in FY2023.
10-K for FY2023, filed Mar 29, 2024
−$125.6MView ↗
10-K for FY2023, filed Mar 29, 2024
−$155.5MView ↗
10-K for FY2023, filed Mar 29, 2024
−$74.9MView ↗
10-Q for Q3 FY2024, filed Nov 19, 2024
−$21.8MView ↗
8-K, filed Mar 18, 2025
On March 18, 2025 (the “Petition Date”), Danimer Scientific, Inc. (the “Company”) and its subsidiaries (together with the Company, the…View ↗
8-K, filed Dec 31, 2024
On December 30, 2024, the New York Stock Exchange (“NYSE”) notified Danimer Scientific Inc. (“Danimer” or the “Company”) that it has…View ↗
Grew. Revenue grew 44% in 4 years, from $32.3M in FY2019 to $46.7M in FY2023, about 10% a year.
Adds a catalytic PHA technology
The latest report adds Rinnovo, a type of PHA produced through a thermal catalytic process, alongside Nodax, which it makes through fermentation; the older report describes PHA production through fermentation.
10-K for FY2020, filed Mar 30, 2021 10-K for FY2023, filed Mar 29, 2024
Competes with The Dow Chemical, E.I. DuPont, BASF, INEOS USA, LyondellBasell Industries, Saudi Basic Industries, Mitsubishi Chemical, Kaneka, Novamont, and CJ CheilJedang
10-K for FY2023, filed Mar 29, 2024Established companies in this segment include The Dow Chemical Company, E.I. DuPont de Nemours and Company, BASF Corporation, INEOS USA…View ↗
Loading...